Satoru Meguro

Dr. Satoru Meguro

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JHJunya Hata
Junya Hata
YHYuki Harigane
Yuki Harigane
KMKanako Matsuoka
Kanako Matsuoka
HAHidenori Akaihata
Hidenori Akaihata
KYKei Yaginuma
Kei Yaginuma
YKYoshiyuki Kojima
Yoshiyuki Kojima
Benign prostatic hyperplasia (BPH) is a chronic proliferative disease showing stromal-dominant proliferation. However, the detailed proliferation mechanism has remained unclear. Although aging and androgen have been reported as definitive risk factors for BPH, recent studies have focused on the involvement of androgen-independent factors. Androgen-independent factors include ischemia, oxidative stress, metabolic syndrome, infection, autoimmune reactions, and inflammation, with inflammation in BPH tissues playing a central role in the BPH proliferative process. Inflammation in BPH tissues by various factors finally leads to tissue remodeling and stromal proliferation through the wound healing process of the prostate. To elucidate the proliferative mechanism of BPH, a study using whole-genome gene expression analysis in a stromal-dominant BPH rat model was performed and showed that immune response-related pathways and complement classical pathways are activated. Furthermore, expression analysis using this BPH rat model showed that the autoimmune reaction triggered complement pathway activation in the proliferative process of BPH. BPH is a multifactorial disease, and understanding the role of androgen-independent factors including immune responses contributes to elucidating the pathogenesis of BPH. Androgen-independent factors may lead to new therapeutic targets for BPH, and further development of this research is expected.

9 September 2024 in Nature Aging
Verified
Journal Article
Open access
PDF file
SMSatoru Meguro
Satoru Meguro
YJYoshikazu Johmura
Yoshikazu Johmura
TWTeh-Wei Wang
Teh-Wei Wang
SKSatoshi Kawakami
Satoshi Kawakami
STShota Tanimoto
Shota Tanimoto
MNMakoto Nakanishi
Makoto Nakanishi
Aging is a major risk factor for cancer, but the precise mechanism by which aging promotes carcinogenesis remains largely unknown. Here, using genetically modified mouse models, we show that p16high senescent (p16h-sn) fibroblasts accumulate with age, constitute inflammatory cancer-associated fibroblasts (CAFs) and promote tumor growth in bladder cancer models. Single-cell RNA sequencing of fibroblasts from aged mice revealed higher expression of the C–X–C motif chemokine 12 gene (Cxcl12) in p16h-sn fibroblasts than in p16low fibroblasts. Elimination of p16h-sn cells or inhibition of CXCL12 signaling notebly suppressed bladder tumor growth in vivo. We identified high expression levels of SMOC2, GUCY1A1 (GUCY1A3), CXCL12, CRISPLD2, GAS1 and LUM as a signature of p16h-sn CAFs in humans and mice, which was associated with age and poor prognosis in patients with advanced and nonadvanced bladder cancer. Here we show that p16h-sn fibroblasts in the aged bladder create a cancer-permissive niche and promote tumor growth by secreting CXCL12.

1 August 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
SHseiji hoshi
seiji hoshi
KYKei Yaginuma
Kei Yaginuma
SMSatoru Meguro
Satoru Meguro
AOAkifumi Onagi
Akifumi Onagi
KMKanako Matsuoka
Kanako Matsuoka
YKYoshiyuki Kojima
Yoshiyuki Kojima
Theranostics (therapy + diagnosis) targeting prostate-specific membrane antigen (PSMA) is an emerging therapeutic modality that could alter treatment strategies for prostate cancer. Although PSMA-targeted radioligand therapy (PSMA-RLT) has a highly therapeutic effect on PSMA-positive tumor tissue, the efficacy of PSMA-RLT depends on PSMA expression. Moreover, predictors of treatment response other than PSMA expression are under investigation. Therefore, the optimal patient population for PSMA-RLT remains unclear. This review provides an overview of the current status of theranostics for prostate cancer, focusing on PSMA ligands. In addition, we summarize various findings regarding the efficacy and problems of PSMA-RLT and discuss the optimal patient for PSMA-RLT.

18 August 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
SMSatoru Meguro
Satoru Meguro
SMSyunta Makabe
Syunta Makabe
KYKei Yaginuma
Kei Yaginuma
AOAkifumi Onagi
Akifumi Onagi
RTRyo Tanji
Ryo Tanji
YKYoshiyuki Kojima
Yoshiyuki Kojima
Since cancer is often linked to the aging process, the importance of cellular senescence in cancer has come under the spotlight. While senescence in cancer cells can serve as a natural barrier against cancer due to its proliferation arrest, its secretory phenotypes and alterations in the surface proteome can paradoxically promote or suppress tumor progression. Senescent cancer-associated fibroblasts, endothelial cells, and immune cells can also contribute to cancer promotion. During therapeutic interventions for cancer, not only their therapeutic effects, but also therapy-induced senescence may have an impact on cancer outcomes. Senotherapeutics, therapy targeting senescent cells, have been reported as novel cancer therapy in recent studies, and the combination of senescence induction and senotherapeutics has been increasingly recognized. Although some clinical trials of senotherapeutic drugs for cancer with or without senescence-inducible therapy are ongoing, there is as yet no satisfactory clinical application. With further research into targeting senescence in oncology, it is expected that senotherapeutics, particularly in combination with senescence-inducing therapy, will become a novel therapeutic strategy.

11 September 2024 in International Journal of Urology
Verified
Journal Article
Closed access
JHJunya Hata
Junya Hata
KMKanako Matsuoka
Kanako Matsuoka
YHYuki Harigane
Yuki Harigane
KYKei Yaginuma
Kei Yaginuma
HAHidenori Akaihata
Hidenori Akaihata
YKYoshiyuki Kojima
Yoshiyuki Kojima

29 December 2022 in Cancer Genomics & Proteomics
Verified
Journal Article
Open access
PDF file
SMSatoru Meguro
Satoru Meguro
TKTomoyuki Koguchi
Tomoyuki Koguchi
YHYusuke Hakozaki
Yusuke Hakozaki
AOAkifumi Onagi
Akifumi Onagi
KMKanako Matsuoka
Kanako Matsuoka
YKYoshiyuki Kojima
Yoshiyuki Kojima
Background/Aim: Several cases of concurrent reduction of expression of polycystin 1 (PKD1) and Tuberous Sclerosis Complex 2 (TSC2) that are contiguous in chromosome 16p13 have been previously reported. This study newly addresses the concurrent reduction of expression of PKD1, TSC2 and NTHL1, which is adjacent to TSC2 and is a tumor suppressor gene. Materials and Methods: We investigated the mRNA expression levels of PKD1, TSC2, PKD2, TSC1 and NTHL1 in blood and renal cell carcinoma (RCC) tissues in a proband with autosomal dominant polycystic kidney disease (ADPKD), tuberous sclerosis complex (TSC) and multiple pathologically diverse RCCs, including clear cell, papillary and chromophobe types. Additionally, we investigated germline variants in blood using whole exome sequencing (WES) in the proband and her four siblings. Results: mRNA expression levels of PKD1, TSC2 and NTHL1 were reduced in the proband’s blood and RCCs, compared with control groups. WES identified one novel variant with amino acid changes in the PKD1 exon in the three subjects with ADPKD, including the proband. Moreover, two variants in the TSC2 intron specific to the proband were also identified. Conclusion: In this study, we report a novel pathogenic variant in the PKD1 exon which likely led to ADPKD, and two variants in the TSC2 intron, which might have led to reduction in the expression of both TSC2 and NTHL1, consequently leading to TSC and multiple pathologically diverse RCCs.